Adam Feuerstein

Boston

Senior Writer, Biotech at STAT

Reporter @statnews. The Harry Kane of biotech. Dog ❤️er. Polk Award winner. #COYS. Said one analyst: The likes of Adam Feuerstein attack viciously.

Articles

Readout LOUD Podcast: What Vinay Prasad's appointment means for FDA

6 days ago | statnews.com | Allison DeAngelis |Adam Feuerstein

What does the appointment of Vinay Prasad as the head of biologic drug evaluation mean for biotechs? Is his fiery public persona suited for government service? We discuss these and other burning questions on a new episode of “The Readout LOUD,” STAT’s biotech podcast. Matt Herper joins Adam and Allison to examine Prasad’s appointment and the band of outsiders now in charge of U.S. health agencies. He and Adam debate just how disruptive Prasad’s tenure could be.
Vinay Prasad is outraged, and now at the FDA. How will biotech deal?

1 week ago | statnews.com | Adam Feuerstein

This story first appeared in Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can sign up here to get it delivered to their inbox. “Just when I thought I was out, they pull me back in.” — Michael Corleone, “Godfather Part III.”I had this thought Monday while out for a walk with Bo: I’m going to write an entirely politics-free newsletter this week.
Vinay Prasad is outraged, and now at the FDA. How will biotech deal?

1 week ago | flipboard.com | Adam Feuerstein

13 hours agoThe Old Man and the AOC. The Gaza Famine Myth. Plus. . . It’s Wednesday, May 7. This is The Front Page, your daily window into the world of The Free Press—and our take on the world at large. Today: Does …1 day agoFDA names oncologist Dr. Vinay Prasad, a Covid vaccine critic, as the new vaccine chiefPrasad was an outspoken critic of the FDA’s response to the pandemic, including the former vaccine chief, Dr. Peter Marks.
Marea drug cuts type of blood fat in half in study

1 week ago | statnews.com | Adam Feuerstein

Marea Therapeutics said Wednesday that an experimental drug reduced by half a type of blood fat called remnant cholesterol — a mid-stage study result that paves the way for further trials and could lead to a new way of treating cardiovascular disease.
Vertex reports an earnings miss and pause on cystic fibrosis trial

1 week ago | statnews.com | Adam Feuerstein |Jason Mast

Vertex Pharmaceuticals on Monday reported disappointing first-quarter earnings impacted by weaker-than-expected sales of its drugs for cystic fibrosis, and little or no contributions from a gene therapy for sickle cell disease and a recently launched pain medicine. A “tolerability issue” caused a temporary pause to an early stage study involving a closely watched, inhaled, mRNA-based therapy for cystic fibrosis, the company said.
Vertex reports an earnings miss and pause on cystic fibrosis trial

1 week ago | flipboard.com | Adam Feuerstein |Jason Mast

1 day agoNutrionist says 'best food for fatty liver' is common hot drink — not green teaA nutritonist has revealed the "best food for a fatty liver" and it's a common hot drink.
Another Cytokinetics own goal leaves investors fuming

1 week ago | statnews.com | Adam Feuerstein

Cytokinetics committed an unforced error that has extended the review of its heart disease drug by three months, knocked down its stock price, and once again, triggered the ire of investors over questionable management decision-making. The Food and Drug Administration “recently notified” Cytokinetics, the company announced Thursday, that the agency required additional time to fully review a safety management plan for the Cytokinetics’ drug aficamten.
Assessing the impact of Trump's first 100 days on science and health policy

1 week ago | statnews.com | Adam Feuerstein |Allison DeAngelis |Elaine Chen

On this week’s episode of the Readout LOUD, we review President Trump’s first 100 days, the return of biotech M&A, strong drug launches, and Eli Lilly’s PBM problem. The first 100 days of the Trump administration have had a profound impact on federal health agencies, medical research, health policy and the biotech and pharmaceuticals industries.
M&A is back, but nothing in biotech is neat or simple

1 week ago | statnews.com | Adam Feuerstein

This story first appeared in Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can sign up here to get it delivered to their inbox. Two acquisitions. Strong drug launches. FDA drug approvals. A rebounding XBI now 18% higher from its recent low. All in, a very pleasant week so far.
Capricor Therapeutics forges ahead with FDA on Duchenne drug, despite political tumult

2 weeks ago | statnews.com | Adam Feuerstein

The Food and Drug Administration is nearly halfway through a review of Capricor Therapeutics’ cell therapy for Duchenne muscular dystrophy. Even with the tumult inside the agency, interactions between the company and the agency staff have been unaffected, according to the company’s chief executive. “The information requests have been flowing on a regular basis and follow-up has been rapid and efficient,” CEO Linda Marbán told me during a phone call Friday.